One might say that in the world of health care, it is, as Dickens wrote in The Tale of Two Cities, “the best of times and the worst of times.”
On one hand, a challenging economic environment has forced many biotechnology and diagnostics companies, whose work underpins personalized medicine, into a period of constriction. Even the world’s largest pharmaceutical companies have not been immune to the economic consequences of the rising cost of research and post-pandemic corrections. Clinical care providers are facing their own crises in providing cost-effective care, forcing many to cut costs and slow their adoption of new technologies and therapies.
But, on the other hand, new scientific breakthroughs are providing unprecedented opportunities to target prevention and treatment strategies to the right patients at the right times. A rapid pace of progress in science and medicine is ushering in a new era of more precise health care that promises better outcomes for patients and more efficiency for health systems. “We may be,” as one columnist wrote, “on the cusp of astonishing innovation — the limits of which aren’t even clear yet.”
Recognizing that the gap between the promise of personalized medicine and its reality has never been greater, PMC is dedicated to accelerating investment in and adoption of personalized medicine, as its new 2023 – 2024 Impact Report shows.
Twenty years ago, President Clinton noted that “human genome research rapidly advances our understanding of the causes of human disease and will serve as the foundation for a new generation of effective treatments, preventive interventions, and cures.”
PMC remains committed to that vision, which, with your help, we can realize.